Limited Period Offer:Be a PRO for 1 month @Rs49/-Multiple payment options available. Know More
you are here: HomeNewsIndia

Covaxin neutralises multiple coronavirus variants, says ICMR

Covaxin has been developed by Hyderabad-based Bharat Biotech in collaboration with the CMR-National Institute of Virology.

April 21, 2021 / 03:24 PM IST
File image of the Covaxin COVID-19 vaccine

File image of the Covaxin COVID-19 vaccine


Covaxin, Bharat Biotech's COVID-19 vaccine, is effective against multiple coronavirus variants, including the double mutant strain, according to a study by the Indian Council of Medical Research (ICMR).

"ICMR study shows COVAXIN neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well," ICMR said in a tweet.

Also read: Bharat Biotech Covaxin demonstrates 78% efficacy in Phase-3 interim analysis

Covaxin has been developed by Hyderabad-based Bharat Biotech in collaboration with the ICMR-National Institute of Virology.

ICMR-NIV has successfully isolated and cultured multiple variants of concern of SARS-CoV-2 virus - B.1.1.7 (the UK variant), B.1.1.28 (Brazil variant ) and B.1.351 (South Africa variant).

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

ICMR-NIV has demonstrated the neutralisation potential of Covaxin against the UK variant and Brazil variants, the apex health research body said.

In a subsequent statement, Bharat Biotech said phase 3 interim analysis results of Covaxin demonstrated that the vaccine has 78 percent efficacy.
Moneycontrol News
first published: Apr 21, 2021 02:10 pm

stay updated

Get Daily News on your Browser
Sections